EA002390B1 - Полиоболочечная вирусная вакцина против вируса иммунного дефицита человека (вич), способ генерации гуморального и/или клеточного иммунного ответа у млекопитающих на вич и бифункциональная плазмида - Google Patents

Полиоболочечная вирусная вакцина против вируса иммунного дефицита человека (вич), способ генерации гуморального и/или клеточного иммунного ответа у млекопитающих на вич и бифункциональная плазмида Download PDF

Info

Publication number
EA002390B1
EA002390B1 EA199800638A EA199800638A EA002390B1 EA 002390 B1 EA002390 B1 EA 002390B1 EA 199800638 A EA199800638 A EA 199800638A EA 199800638 A EA199800638 A EA 199800638A EA 002390 B1 EA002390 B1 EA 002390B1
Authority
EA
Eurasian Patent Office
Prior art keywords
hiv
recombinant
vaccine
virus
protein
Prior art date
Application number
EA199800638A
Other languages
English (en)
Russian (ru)
Other versions
EA199800638A1 (ru
Inventor
Джулиа Хурвитц
Кристофер Колеклаф
Рэндалл Оуэнз
Карен Слобод
Original Assignee
Снт. Джууд Чилдренс Рисерч Хоспитл
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Снт. Джууд Чилдренс Рисерч Хоспитл filed Critical Снт. Джууд Чилдренс Рисерч Хоспитл
Publication of EA199800638A1 publication Critical patent/EA199800638A1/ru
Publication of EA002390B1 publication Critical patent/EA002390B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus human T-cell leukaemia-lymphoma virus
    • C07K14/155—Lentiviridae, e.g. human immunodeficiency virus [HIV], visna-maedi virus or equine infectious anaemia virus
    • C07K14/16—HIV-1 ; HIV-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24171—Demonstrated in vivo effect
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Communicable Diseases (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
EA199800638A 1996-01-23 1997-01-23 Полиоболочечная вирусная вакцина против вируса иммунного дефицита человека (вич), способ генерации гуморального и/или клеточного иммунного ответа у млекопитающих на вич и бифункциональная плазмида EA002390B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/590,288 US5741492A (en) 1996-01-23 1996-01-23 Preparation and use of viral vectors for mixed envelope protein vaccines against human immunodeficiency viruses
PCT/US1997/000669 WO1997027311A1 (en) 1996-01-23 1997-01-23 Mixture of recombinant vaccinia vectors as polyenv vaccines for hiv

Publications (2)

Publication Number Publication Date
EA199800638A1 EA199800638A1 (ru) 1999-02-25
EA002390B1 true EA002390B1 (ru) 2002-04-25

Family

ID=24361647

Family Applications (1)

Application Number Title Priority Date Filing Date
EA199800638A EA002390B1 (ru) 1996-01-23 1997-01-23 Полиоболочечная вирусная вакцина против вируса иммунного дефицита человека (вич), способ генерации гуморального и/или клеточного иммунного ответа у млекопитающих на вич и бифункциональная плазмида

Country Status (28)

Country Link
US (3) US5741492A (enExample)
EP (2) EP0876498B1 (enExample)
JP (2) JP2000504326A (enExample)
KR (1) KR100571479B1 (enExample)
CN (1) CN1229501C (enExample)
AP (1) AP1200A (enExample)
AT (1) ATE278790T1 (enExample)
AU (1) AU709174B2 (enExample)
BG (1) BG64711B1 (enExample)
BR (1) BR9707611A (enExample)
CA (1) CA2243570C (enExample)
CZ (1) CZ296575B6 (enExample)
DE (1) DE69731075T2 (enExample)
DK (1) DK0876498T3 (enExample)
EA (1) EA002390B1 (enExample)
ES (1) ES2230596T3 (enExample)
GE (1) GEP20032902B (enExample)
HU (2) HU0402182D0 (enExample)
IL (2) IL125497A (enExample)
NO (1) NO322261B1 (enExample)
NZ (1) NZ331024A (enExample)
OA (1) OA10814A (enExample)
PL (1) PL188641B1 (enExample)
PT (1) PT876498E (enExample)
RO (1) RO120268B1 (enExample)
TR (1) TR199801418T2 (enExample)
UA (1) UA73712C2 (enExample)
WO (1) WO1997027311A1 (enExample)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7488485B2 (en) * 2003-09-16 2009-02-10 University Of Kansas Medical Center DNA vaccine compositions and methods of use
US20030138454A1 (en) * 1997-06-09 2003-07-24 Oxxon Pharmaccines, Ltd. Vaccination method
GB9711957D0 (en) * 1997-06-09 1997-08-06 Isis Innovation Methods and reagents for vaccination
US6919318B1 (en) * 1998-04-22 2005-07-19 Chiron Corporation Enhancing immune responses to genetic immunization by using a chemokine
WO1999061049A2 (en) * 1998-05-22 1999-12-02 University Of Massachusetts Medical Center Model for infection by a pathogen using administration of nucleic acids
US6562800B1 (en) * 1998-10-30 2003-05-13 University Of Southern California Use of immunopotentiating sequences for inducing immune response
US6759237B1 (en) * 1998-11-05 2004-07-06 The Trustees Of The University Of Pennsylvania Adeno-associated virus serotype 1 nucleic acid sequences, vectors and host cells containing same
EP1135468B1 (en) 1998-11-10 2010-01-06 University Of North Carolina At Chapel Hill Virus vectors and methods of making and administering the same
EP1141314A2 (en) * 1998-12-31 2001-10-10 Chiron Corporation Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof
US7935805B1 (en) * 1998-12-31 2011-05-03 Novartis Vaccines & Diagnostics, Inc Polynucleotides encoding antigenic HIV Type C polypeptides, polypeptides and uses thereof
AU2221600A (en) 1998-12-31 2000-07-31 Chiron Corporation Improved expression of hiv polypeptides and production of virus-like particles
ATE384795T1 (de) * 1998-12-31 2008-02-15 Novartis Vaccines & Diagnostic Modifizierte hiv env polypeptide
CA2361353A1 (en) * 1999-01-28 2000-08-03 Stichting Biomedical Primate Research Centre Product and method for obtaining specific immunisation with one or more antigens
DE19907485B4 (de) * 1999-02-12 2008-01-17 Strathmann Ag & Co. Virus-Vakzine
US6420545B1 (en) * 1999-05-24 2002-07-16 The Trustees Of The University Of Pennsylvania CD4-independent HIV envelope proteins as vaccines and therapeutics
AU3793701A (en) * 1999-11-29 2001-06-04 Orchid Biosciences, Inc. Methods of identifying optimal drug combinations and compositions thereof
US20040105871A1 (en) * 2000-03-02 2004-06-03 Robinson Harriet L. Compositions and methods for generating an immune response
US20020106798A1 (en) 2000-03-02 2002-08-08 Robinson Harriet L. DNA expression vectors and methods of use
US8623379B2 (en) * 2000-03-02 2014-01-07 Emory University Compositions and methods for generating an immune response
WO2002011748A1 (en) * 2000-08-07 2002-02-14 Sloan-Kettering Institute For Cancer Research Method and composition for immunization using mixed pools of mutated nucleic acids or peptides
AU2002305914A1 (en) * 2001-01-12 2002-10-21 Chiron Corporation Nucleic acid mucosal immunization
CN100446812C (zh) * 2001-03-08 2008-12-31 美国国有健康与人类服务部 表达修饰的hiv包膜、gag和pol基因的mva
AU2002320314A1 (en) 2001-07-05 2003-01-21 Chiron, Corporation Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof
EP1409694A4 (en) * 2001-07-05 2006-02-08 Chiron Corp POLYNUCLEOTIDES ENCODING ANTIGENIC POLYPEPTIDES OF HIV SUBTYPE B AND / OR SUBTYPE C, POLYPEPTIDES AND USES THEREOF
GB0118532D0 (en) * 2001-07-30 2001-09-19 Isis Innovation Materials and methods relating to improved vaccination strategies
CA2458995C (en) * 2001-08-31 2013-04-30 Chiron Corporation Polynucleotides encoding antigenic hiv type b polypeptides, polypeptides and uses thereof
US20030170614A1 (en) * 2001-08-31 2003-09-11 Megede Jan Zur Polynucleotides encoding antigenic HIV type B polypeptides, polypeptides and uses thereof
US20070269456A1 (en) * 2001-11-05 2007-11-22 Lasher Alfred W DNA-based plasmid formulations and vaccines and prophylactics containing the same
US20030228327A1 (en) * 2001-11-05 2003-12-11 Lasher Alfred W. DNA-based plasmid formulations and vaccines and prophylactics containing the same
GB2396814B (en) 2001-11-30 2006-07-19 Isis Innovation Fowlpox vector
US7094410B2 (en) * 2002-03-02 2006-08-22 The Scripps Research Institute DNA vaccine against proliferating endothelial cells and methods of use thereof
US6923958B2 (en) * 2002-03-02 2005-08-02 The Scripps Research Institute DNA vaccines encoding CEA and a CD40 ligand and methods of use thereof
US20040106566A1 (en) * 2002-05-17 2004-06-03 Shi-Lung Lin RNA-splicing and processing-directed gene silencing and the relative applications thereof
DE60324678D1 (de) * 2002-07-18 2008-12-24 Univ Washington N t-lymphozyten und damit identifizierte hsv-antigene
US7901690B2 (en) * 2002-12-03 2011-03-08 University Of Massachusetts Polyvalent, primary HIV-1 glycoprotein DNA vaccines and vaccination methods
BRPI0410422A (pt) 2003-05-12 2006-05-30 Univ Florida materiais e processos para para imunização contra infecção por fiv
US7658927B2 (en) * 2003-05-12 2010-02-09 University Of Florida Research Foundation, Inc. Materials and methods for immunizing against FIV infection
US8076060B2 (en) * 2003-08-04 2011-12-13 Emil William Chynn Vaccination and immunotherapy as new therapeutic modalities in the treatment of glaucoma
AU2004270275B2 (en) * 2003-09-09 2010-02-18 Virxsys Corporation Lentivirus vector-based approaches for generating an immune response to HIV humans
WO2005027840A2 (en) * 2003-09-15 2005-03-31 Chiron Corporation Combination approaches for generating immune responses
CN1913919B (zh) 2003-09-15 2011-10-19 美国政府健康及人类服务部 基于hiv多进化枝的env的hiv疫苗
US20050175627A1 (en) * 2003-09-24 2005-08-11 Oxxon Therapeutics Ltd. HIV pharmaccines
US7622125B2 (en) 2004-05-05 2009-11-24 Novartis Vaccines And Diagnostics, Inc. Polycistronic HIV vector constructs
CN100549021C (zh) * 2004-05-27 2009-10-14 森托科尔公司 猕猴前列腺特异性抗原
EP1773406A4 (en) * 2004-06-15 2008-09-03 Centocor Inc METHOD FOR SCREENING AGENTS AGAINST DISEASE OF HUMAN PROSTATE
EP2397490B1 (en) 2004-07-16 2013-09-04 THE UNITED STATES OF AMERICA, represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Vaccine constructs and combinations of vaccines designed to improve the breadth of the immune response to diverse strains and clades of HIV
WO2006044864A2 (en) * 2004-10-19 2006-04-27 Duke University Vaccine adjuvant
WO2006050394A2 (en) 2004-11-01 2006-05-11 Novartis Vaccines And Diagnostics Inc. Combination approaches for generating immune responses
EP1828390B1 (en) * 2004-12-15 2012-06-13 The University Of North Carolina At Chapel Hill Chimeric vectors
WO2008048984A2 (en) * 2006-10-18 2008-04-24 St. Jude Children's Research Hospital Methods and compositions for preparing a universal influenza vaccine
EP2396343B1 (en) 2009-02-11 2017-05-17 The University of North Carolina At Chapel Hill Modified virus vectors and methods of making and using the same
EA025417B1 (ru) * 2010-11-22 2016-12-30 Борис Славинович ФАРБЕР Вакцины с повышенной иммуногенностью и способы их получения
WO2012106363A2 (en) 2011-01-31 2012-08-09 Intellect Neurosciences Inc. Treatment of tauopathies
ES2606511T3 (es) 2011-04-06 2017-03-24 Biovaxim Limited Composiciones farmacéuticas para prevenir y/o tratar una enfermedad por VIH en seres humanos
MX2014005548A (es) 2011-11-14 2014-08-21 Novartis Ag Complejos inmunogenicos de carbomeros polianionicos y polipeptidos env y metodos de manufactura y usos de los mismos.
US9833503B2 (en) 2012-02-24 2017-12-05 President And Fellows Of Harvard College Methods for displaying polypeptides and uses thereof
PL3390430T3 (pl) * 2015-12-15 2020-03-31 Janssen Vaccines & Prevention B.V. Antygeny ludzkiego wirusa niedoboru odporności, wektory, kompozycje i sposoby ich zastosowania
CN113874078B (zh) 2019-04-05 2025-05-06 Tauc3生物制品有限公司 抗tauc3抗体及其应用
IT202100000569A1 (it) * 2021-01-14 2022-07-14 Evobiotech S R L Composizione comprendente vescicole extracellulari vegetali ingegnerizzate e suo impiego come vaccino

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2181435A (en) * 1985-09-25 1987-04-23 Oncogen Vaccines and immunoassays for acquired immune deficiency syndrome
WO1990012880A1 (en) * 1989-04-18 1990-11-01 Applied Biotechnology, Inc. Generation of hybrid genes and proteins by virus-mediated recombination
WO1992022641A1 (en) * 1991-06-14 1992-12-23 Virogenetics Corporation Immunodeficiency virus recombinant poxvirus vaccine

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5198214A (en) * 1983-08-31 1993-03-30 Stolle Research & Development Corporation Anti-mastitis polyvalent vaccine, method of administration and method for production thereof
US5169763A (en) * 1986-04-08 1992-12-08 Transgene S.A., Institut Pasteur Viral vector coding glycoprotein of HIV-1
EP0243029A1 (en) * 1986-04-08 1987-10-28 THE UNITED STATES OF AMERICA as represented by the Secretary United States Department of Commerce Recombinant vaccinia virus expressing human retrovirus gene
US5081226A (en) * 1986-12-30 1992-01-14 The United States Of America As Represented By The Department Of Health And Human Services Synthetic peptides sharing sequence homology with the HIV envelope protein
US5643578A (en) * 1992-03-23 1997-07-01 University Of Massachusetts Medical Center Immunization by inoculation of DNA transcription unit
ATE475668T1 (de) * 1994-01-27 2010-08-15 Univ Massachusetts Medical Immunisierung durch impfung von dns transkriptionseinheit
FR2728794B1 (fr) * 1994-12-30 1997-03-21 Rhone Merieux Vaccin recombinant aviaire a base de virus herpes aviaire, notamment contre la maladie de gumboro

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2181435A (en) * 1985-09-25 1987-04-23 Oncogen Vaccines and immunoassays for acquired immune deficiency syndrome
WO1990012880A1 (en) * 1989-04-18 1990-11-01 Applied Biotechnology, Inc. Generation of hybrid genes and proteins by virus-mediated recombination
WO1992022641A1 (en) * 1991-06-14 1992-12-23 Virogenetics Corporation Immunodeficiency virus recombinant poxvirus vaccine

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
AIDS RESEARCH AND HUMAN RETROVIRUSES, vol. 11, no. 9, September 1995, pages 1131-1133, XP000671832, RENCHER. S.D. ET AL.: "Does the key to a successful HIV type 1 vaccine lie among the envelope sequences of infected individuals", see the whole document *
IMMUNOLOGY AND CELL BIOLOGY, vol. 68, 1 January 1990, pages 113-117, XP000351945, RUBY J ET AL: "RESPONSE OF MONKEYS TO VACCINATION WITH RECOMBINANT VACCINIA VIRUS WHICH COEXPRESS HIV GP160 AND HUMAN INTERLEUKIN-2", see the whole document *
JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES AND HUMAN RETROVIROLOGY, vol. 10, no. 1, 1 September 1995, pages 27-35, XP000671822, PERALES, M.A. ET AL.: "A Vaccinia-gp160-based vaccine but not a gp160 protein vaccine elicits anti-gp160 cytotoxic T lymphocytes in some HIV-1 seronegytive vaccinees", see the whole document *
JOURNAL OF VIROLOGY, vol. 64, no. 12, 1 December 1990, pages 5948-5957, XP000351687, GRITZ L ET AL: "GENERATION OF HYBRID GENES AND PROTEINS BY VACCINIA VIRUS-MEDIATED RECOMBINATION: APPLICATION TO HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 ENV", see the whole document *

Also Published As

Publication number Publication date
EP0876498A1 (en) 1998-11-11
BG64711B1 (bg) 2005-12-30
EP0876498B1 (en) 2004-10-06
US5846546A (en) 1998-12-08
CN1229501C (zh) 2005-11-30
US5741492A (en) 1998-04-21
AP1200A (en) 2003-08-29
KR100571479B1 (ko) 2007-06-07
PL188641B1 (pl) 2005-03-31
RO120268B1 (ro) 2005-11-30
TR199801418T2 (xx) 1998-10-21
UA73712C2 (en) 2005-09-15
JP2007259870A (ja) 2007-10-11
CN1214083A (zh) 1999-04-14
IL125497A0 (en) 1999-03-12
AP9801325A0 (en) 1998-09-30
IL125497A (en) 2007-07-04
CZ229398A3 (cs) 1998-12-16
NO983377D0 (no) 1998-07-22
NZ331024A (en) 2000-02-28
CA2243570A1 (en) 1997-07-31
HK1016218A1 (en) 1999-10-29
ATE278790T1 (de) 2004-10-15
DE69731075T2 (de) 2006-03-09
KR19990081931A (ko) 1999-11-15
HU224344B1 (hu) 2005-08-29
BG102712A (en) 1999-04-30
DK0876498T3 (da) 2005-02-07
EA199800638A1 (ru) 1999-02-25
PT876498E (pt) 2005-02-28
AU709174B2 (en) 1999-08-26
EP1378516A1 (en) 2004-01-07
US6086891A (en) 2000-07-11
HU0402182D0 (en) 2004-12-28
PL328193A1 (en) 1999-01-18
JP2000504326A (ja) 2000-04-11
AU1829997A (en) 1997-08-20
NO322261B1 (no) 2006-09-04
GEP20032902B (en) 2003-02-25
HUP9900389A3 (en) 2001-06-28
CZ296575B6 (cs) 2006-04-12
WO1997027311A1 (en) 1997-07-31
ES2230596T3 (es) 2005-05-01
BR9707611A (pt) 1999-07-27
CA2243570C (en) 2001-08-14
IL156919A0 (en) 2004-02-08
OA10814A (en) 2003-01-28
NO983377L (no) 1998-09-23
HUP9900389A2 (hu) 1999-06-28
DE69731075D1 (de) 2004-11-11

Similar Documents

Publication Publication Date Title
ES2230596T3 (es) Mezcla de vectores de vaccinia recombinantes como vacunas poligueur contra el vih.
US20230330215A1 (en) Sars-cov-2 vaccines
ES2640961T3 (es) Virus de la estomatitis vesicular para vacunas de sensibilización y refuerzo
US20100291037A1 (en) Immunogenicity using a combination of dna and vaccinia virus vector vaccines
JP2022539417A (ja) Ｈｉｖ抗原及びｍｈｃ複合体
CA3173795A1 (en) Attenuated poxvirus vector based vaccine for protection against covid-19
JP2023521662A (ja) 感染症抗原及びワクチン
AU2001259291A1 (en) Improved immunogenicity using a combination of DNA and vaccinia virus vector vaccines
WO2014093602A1 (en) Compositions and methods for treating and preventing hepatitis c virus infection
Zhang et al. Comparison of heterologous prime-boost immunization strategies with DNA and recombinant vaccinia virus co-expressing GP3 and GP5 of European type porcine reproductive and respiratory syndrome virus in pigs
US20190022212A1 (en) Methods for safe induction of cross-clade immunity against human immunodeficiency virus infection in human
JP2010528603A (ja) ネコ抗原のアライグマポックスウイルス発現遺伝子
US9000136B2 (en) Recombinant vaccinia virus having hepatitis C virus gene
US20240181041A1 (en) Adenovirus SARS-CoV-2 Vaccine
CN115990249B (zh) 一种登革四价dna疫苗及其应用
JPH10512151A (ja) Ｈｔｌｖ抗原を発現する組換え弱毒化ポックスウイルスを含有する免疫原性組成物
EP4305156A1 (en) Bovine viral diarrhea virus immunogenic compositions and methods of use thereof
ES2252918T3 (es) Cepa fiv-141 del virus de la inmunodeficiencia felina y sus usos.
US20030124146A1 (en) Recombinant Rhabdoviruses as live-viral vaccines
JP2002501369A (ja) Ｆｉｖワクチン
US6723558B1 (en) Preparation and use of viral vectors for mixed envelope protein vaccines against human immunodeficiency viruses
HK1016218B (en) Mixture of recombinant vaccinia vectors as polygeur vaccines for hiv
Gardner Genetic Immunization for Lentiviral Immunodeficiency Virus Infection and Disease.
HK1238577A1 (en) Methods and compositions for inducing protective immunity against human immunodeficiency virus infection
HK1238577B (en) Methods and compositions for inducing protective immunity against human immunodeficiency virus infection

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM RU